StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Equities researchers at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued on Sunday. The brokerage set a “sell” rating on the medical technology company’s stock.

A number of other analysts have also weighed in on the stock. Benchmark restated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd. Ascendiant Capital Markets dropped their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

BIOLASE Price Performance

BIOL opened at $0.01 on Friday. The stock has a market capitalization of $250,552.50, a price-to-earnings ratio of 0.00 and a beta of 0.67. The business has a fifty day moving average price of $0.01 and a 200 day moving average price of $0.05. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.